GU toxicity determined by germline variants in retrospective prostate cancer study

“What we found was a signature that you can apply to patients to find out whether they're at high risk of these moderate or greater urinary side effects in the long term, and it did appear to depend on the type of radiation they were receiving,” says Amar U. Kishan, MD.

In this video, Amar U. Kishan, MD, discusses the results of the study, “Germline variants disrupting microRNAs predict long-term genitourinary toxicity after prostate cancer radiation.” Kishan is an associate professor in the department of radiation oncology, chief of genitourinary oncology service, and vice chair of clinical and translational research at the University of California, Los Angeles.